0001562180-20-004869.txt : 20200702
0001562180-20-004869.hdr.sgml : 20200702
20200702181453
ACCESSION NUMBER: 0001562180-20-004869
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200630
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paggiarino Dario A.
CENTRAL INDEX KEY: 0001574261
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 201011319
MAIL ADDRESS:
STREET 1: 4025 SORRENTO VALLEY BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-06-30
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001574261
Paggiarino Dario A.
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
Chief Medical Officer
Common Stock
2020-06-30
4
M
false
41050.00
0.00
A
101193.00
D
Common Stock
2020-06-30
4
F
false
12049.00
0.757
D
89144.00
D
Restricted Stock Units
0.00
2020-06-30
4
M
false
41050.00
0.00
D
Common Stock
41050.00
82100.00
D
No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022.
/s/ John Mercer, Attorney-in-Fact
2020-07-02